Halozyme Inc. (HALO) Market Capitalization to Book Value Ratio

Corporate emblem and logo of Halozyme Inc. (HALO)

Halozyme Therapeutics (HALO) generates revenue by licensing an innovative subcutaneous drug delivery method, collecting substantial royalties. This chart of market and book valuation metrics on GURU.Markets reflects the price action, where the current value stands at 104.91. Price stability is supported by a streamlined distribution of enzymes, while the business relies on production outsourcing, shifting manufacturing to external contract partners.

Halozyme Therapeutics (HALO) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/30/2026
Flagship merchandise of Halozyme Therapeutics, Inc.

This indicator determines the size of the market premium an investor pays for every dollar of the company's net assets, allowing for the differentiation of actual asset value from market expectations. For Halozyme Therapeutics (HALO), whose stability is ensured by a diversified royalty stream from the licensing of Enhanze technology, the market capitalization-to-book value ratio reflects the extent to which intellectual property is capitalized within the business's fundamental valuation.

Who Halozyme Therapeutics competes with

BeiGene Ltd (ONC) - Market Value to Book Value Ratio|Market-to-Book Ratio revmed.com (RVMD)|AAPG (Ascentage Pharma) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio CG Oncology Inc (CGON)|Market Capitalization to Book Value Ratio URGN|Market Capitalization to Book Value Ratio Bicara Corp (BCAX)|Market Value to Book Value Ratio Personalis, Inc. PSNL|ERAS: Capitalization to Book Value Ratio|Delcath Systems - Market Capitalization to Book Value Ratio|Y-mAbs Therapeutics Inc (YMAB) - Market Cap to Net Assets Ratio|AURA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Candel Therapeutics, Inc. (CADL)|Market Value to Book Value Ratio Accuray Incorporated|SLS: Market Value to Book Value|Market Cap to Net Assets Ratio ACTU (Actuate Therapeutics)|CTOR (Citius Oncology Inc.) - Market Value to Book Value|Market Capitalization to Book Value Ratio HURA (TuHURA Biosciences)|TARA - Market Cap to Net Assets Ratio|FATE: Market Cap to Net Assets Ratio|WHWK - Market Capitalization to Book Value Ratio|tscan.com (TCRX) - Market Value to Book Value Ratio|Champions Oncology, Inc. - Market Value to Book Value|XBIT (XBiotech Inc) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio CEL-SCI Corp CVM|Market Capitalization to Book Value Ratio OSTX|RADX (Radiopharm Theranostics Ltd) - Market Value to Book Value|Market Capitalization to Book Value Ratio ARTV (Artiva Biotherapeutics)|Market Capitalization to Book Value Ratio Adlai Nortye Ltd ANL|VERU - Market Value to Book Value Ratio|TPST: Market Value to Book Value Ratio|xiliotx.com (XLO) - Market Value to Book Value Ratio|Market-to-Book Ratio Renovaro (RENB)|Market Cap to Net Assets Ratio MURA|Kairos Pharma Inc - Market Capitalization to Net Assets|Market Cap to Net Assets Ratio OKUR (OnKure Therapeutics Inc)|GDTC - Market-to-Book Ratio|Market Value to Book Value Ratio Curis CRIS|APLM - Market Cap to Net Assets Ratio|Tharimmune - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Advanced Biomed Inc|GNPX (Genprex, Inc) - Market Cap to Net Assets Ratio|Calidi Biotherapeutics, Inc. - Market Value to Book Value|Market Cap to Net Assets Ratio SBFM|XBIO (Xenetic Bio) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio SLRX|PPBT (Purple Biotech Ltd) - Market Value to Book Value|Market Capitalization to Book Value Ratio AONC (American Oncology Network, Inc.)|BeiGene Ltd (BGNE) - Market-to-Book Ratio|CKPT - Market Value to Book Value Ratio|Market Value to Book Value ELEV (Elevation Oncology Inc.)|ICAD: Market Capitalization to Book Value Ratio|Ikena Oncology (IKNA) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Notable Labs Inc.|Viracta - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio MOR|NAYA - Market-to-Book Ratio|Ascentage Pharma - Market Cap to Net Assets Ratio